1056159-15-9 Usage
Uses
Used in Pharmaceutical Synthesis:
(3S)-1-phenylpiperidine-3-carboxylic acid serves as a key intermediate in the development of pharmaceuticals. Its specific stereochemistry and functional groups enable it to be a versatile building block for the creation of new drugs with potential therapeutic applications.
Used in Research Chemicals:
In the realm of scientific research, (3S)-1-phenylpiperidine-3-carboxylic acid is utilized as a research chemical. It aids chemists and biologists in studying the effects of stereochemistry on biological activity and in developing a deeper understanding of molecular interactions.
Used in Drug Development for Neurological Disorders:
Given its potential biological activity, (3S)-1-phenylpiperidine-3-carboxylic acid may be employed in the development of new drugs targeting neurological disorders. Its unique structure could allow for the design of medications that interact with specific receptors or pathways implicated in such conditions.
Used as a Precursor in Organic Synthesis:
(3S)-1-phenylpiperidine-3-carboxylic acid also functions as a precursor in organic synthesis, allowing for the creation of a variety of complex organic molecules. Its presence as a chiral center and the presence of a phenyl ring and carboxylic acid group make it a useful starting material for the synthesis of other compounds with specific properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1056159-15-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,6,1,5 and 9 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1056159-15:
(9*1)+(8*0)+(7*5)+(6*6)+(5*1)+(4*5)+(3*9)+(2*1)+(1*5)=139
139 % 10 = 9
So 1056159-15-9 is a valid CAS Registry Number.
1056159-15-9Relevant academic research and scientific papers
N-substituted piperidines and their use as pharrmaceuticals
-
Page/Page column 49, (2010/02/15)
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
